Abstract
The Apolipoprotein epsilon 4 (APOE e4) genetic variant is notoriously linked to enhanced risk of developing Alzheimer's Disease (AD). Several studies have examined how this allele could influence cognitive functioning in healthy adults, and whether e4 carriers show a subtle cognitive decline that would indicate preclinical AD pathology. Research has predominantly focused on episodic memory, where e4 carriers are usually impaired, while semantic memory functioning has received less attention. To evaluate current evidence on the influence of APOE e4 on semantic memory, we systematically reviewed the research literature assessing semantic memory in non-clinical adult populations according to the PRISMA guidelines. We reviewed 17 articles that revealed high heterogeneity in how semantic memory is conceptualised and assessed. When tested via standard neuropsychological tests (verbal fluency, naming, language comprehension and general knowledge), e4 carriers did not significantly differ from non-carriers. Instead, e4 carriers showed lower performance than non-carriers when assessed via more complex semantic memory tasks (longer verbal fluency tasks, autobiographical memory tasks, and measures of semantic clustering). The impact of APOE e4 on semantic memory thus appears to be restricted to these more complex tasks, which could constitute a better match to episodic memory tasks for which APOE effects are typically observed. Future research investigating autobiographical memory retrieval in e4 carriers could provide a more sensitive and ecologically valid assessment of semantic memory and would disentangle between personal and general forms of semantic memory.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was completed as part of Riccardo Sacripants's thesis portfolio for the Doctorate of Clinical Psychology (ClinPsyD) at the University of East Anglia. Dr. Louis Renoult was supported by Grant MR/S011463/1 from the Medical Research Council (MRC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.